The Obesity Epidemic

The obesity epidemic and health risks

Excess weight increases the risk of a number of medical conditions, such as high blood pressure, high cholesterol, heart disease and some cancers. Obesity is also associated with reduced fertility, an increase in mental health problems and numerous joint and mobility problems.

NICE-approved medical weight loss in the UK: Wegovy and Mounjaro in 2026

For adults who meet licensing and eligibility criteria, Wegovy (semaglutide) and Mounjaro (tirzepatide) are now the dominant injectable treatments discussed in UK clinical practice for obesity alongside diet and exercise. Both have NICE technology appraisal routes relevant to weight management in eligible patients; availability on the NHS varies by commissioning, which is why many people explore private weight management with UK-registered prescribers.

Wegovy (semaglutide): weekly GLP-1 therapy

Wegovy is a once-weekly injection that mimics GLP-1, a hormone involved in appetite and satiety. It is licensed for weight management in adults with obesity, or overweight with at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity, when prescribed appropriately. Clinical trials have shown meaningful weight reduction for many patients; cardiovascular outcome data also supports its role in selected populations. Your clinician will assess suitability, titration, and monitoring.

Mounjaro (tirzepatide): dual GLP-1 and GIP action

Mounjaro (tirzepatide) is a once-weekly injection that activates both GLP-1 and GIP receptors. In eligible patients it is used for weight management alongside diet and activity. Many patients and clinicians compare options when discussing Wegovy vs Mounjaro: mechanisms differ, response varies individually, and the right choice depends on medical history, tolerability, and shared decision-making, not marketing claims.

Weekly injectables versus older daily GLP-1

Clinical discussion for new injectable anti-obesity treatment in the UK now usually centres on once-weekly Wegovy (semaglutide) and Mounjaro (tirzepatide), used with diet and activity when licensed criteria are met. Mounjaro adds a GIP pathway alongside GLP-1; both require supervised titration and follow-up. The daily high-dose liraglutide pen format—often supplied as Nevolat (authorised generic liraglutide)—remains in use for some individuals, but it is no longer the main reference point when people ask what “a GLP-1 injection for weight loss” looks like in 2026.

For fuller side-by-side detail (and to avoid repeating long comparison tables here), see our Mounjaro vs Wegovy guide, the broader Mounjaro vs Wegovy, daily liraglutide, and related medicines overview, and what Nevolat means for patients if you are weighing generic liraglutide against other options.

Older tablet options and NHS context

There are several approaches on the NHS. Alongside newer injectables where funded, Xenical (orlistat) remains an oral option: it reduces fat absorption and can be effective, but gastrointestinal side effects lead some patients to stop. Mysimba is a tablet option that has not received a NICE recommendation for routine NHS use in the same way; it may be accessed privately where appropriate.

Access to newer weekly injectables and other anti-obesity medicines through the NHS is often limited by local funding and tiered weight management services. Patients who do not meet local criteria may still benefit from structured private weight loss treatment after a full clinical assessment.

Bariatric surgery compared with newer medications

Bariatric (weight loss) surgery has been available for many years and techniques have improved over time. It remains highly effective for many people living with severe obesity, particularly when delivered within specialist multidisciplinary services. Long-term outcomes depend on follow-up, nutrition, and lifelong behaviour change.

The newest generation of anti-obesity medications, including high-dose semaglutide and tirzepatide, has narrowed the gap for some patients who previously might have seen surgery as the only path to large sustained weight loss. Medications do not replace surgery for everyone: anatomy, comorbidities, prior treatments, and personal preference all matter. What has changed is that medical therapy can now achieve weight reductions that were uncommon with older drugs alone, so the conversation is increasingly about timing, eligibility, and risk-benefit with your surgical and medical teams.

Urgent action is still required to combat obesity

The number of people living with obesity in the UK has risen substantially over the past two decades, and evidence continues to link excess weight to cancer risk, cardiovascular disease, and type 2 diabetes.

Historical context: during the Covid-19 pandemic (2020–2021), higher BMI was associated with worse outcomes from acute infection, and periods of lockdown contributed to more sedentary behaviour for many. In the years since, public health focus has shifted toward long-term prevention, treatment access, and integrating medical and lifestyle support rather than treating the pandemic as a “current” driver of daily risk.

What remains clear is that obesity is multifactorial: diet and exercise are only part of the equation.

Clinicians across the UK contributed to national conversations on obesity strategy after the acute pandemic phase, including input from specialists such as those at PrivateDoc, covering areas from food environment to clearer calorie information in out-of-home settings.

Modern medical weight loss treatments in 2026: calorie balance and clinical support

Ultimately, weight change still reflects energy balance over time: the calories you use versus those you take in. Online calculators for basal metabolic rate (BMR) can be a starting point, but they are averages; two people of the same weight can differ in expenditure and appetite regulation.

Practical self-monitoring often uses a two-week calorie target with regular weights to personalise intake. Medications help by reducing hunger and improving satiety for many patients on GLP-1 weight loss UK pathways, so sticking to a plan becomes more achievable alongside dietitian input and follow-up.

Medications alter how many patients experience hunger and fullness. Once-weekly semaglutide and tirzepatide use stepwise dose increases and ongoing monitoring; gastrointestinal side effects are common across the GLP-1 class and need medical support, especially after dose changes—do not adjust or stop treatment without your prescriber.

In primary and specialist care we still see measurable benefits from sustained weight loss: improved blood pressure, remission or improvement in type 2 diabetes for some, and reduced medication burden. Not everyone will reverse every condition; chronic changes can persist.

Obesity carries physical and emotional dimensions. Drugs are rarely the sole answer: structured eating patterns, activity, sleep, and behavioural support remain essential. Trials of newer weekly agents have, on average, reported larger weight reductions than older oral or daily injectable options for many cohorts; your clinician can put trial figures in context for you.

Weekly injectables in practice: what to expect in 2026

If you are discussing Wegovy or Mounjaro, expect a prescriber-led titration plan, clear advice on diet and physical activity, and follow-up to manage tolerability and safety. These are not “set and forget” prescriptions: dose changes, intercurrent illness, other medicines, and weight-related conditions can all affect suitability over time.

Side effects: nausea, reflux, bloating, and bowel habit changes remain the most familiar issues when starting or stepping up GLP-1-based therapy, whichever weekly product is used. Strategies and timing of dose adjustments should be agreed with your clinician rather than changed on your own.

Daily liraglutide (Nevolat): a minority of pathways still use this older daily pen for selected patients. Practical questions (pen duration, titration) are covered in our Nevolat hub and how long does a Nevolat pen last? guide. Starting, switching, or stopping any anti-obesity medicine should always be clinician-led.